IVERIC bio, Inc. ISEE
Set alert
39.95 +39.95 —
Day range unavailable
52-week range unavailable
- Open
- —
- Prev close
- 0.00
- Mkt cap
- 5.51B
- Vol
- 0
- Avg vol
- 0
- EPS
- 0.00
- P/E
- 0.00
- Div yield
- 0.00%
More statistics
- Low
- —
- High
- —
- Forward P/E
- -26.99
- Beta
- 1.10
- Short ratio
- 5.25
- Inst. own
- 109.36%
- Dividend
- 0.00
- Ex-div date
- Earnings
- Jul 25, 2023
- 50-d avg
- 38.32
- 200-d avg
- 26.70
- 1y target
- 38.50
Analyst view
Consensus: hold
Hold
Price target (mean) 38.50 -3.6% downside
Now 39.95
- Target (low)
- 31.00
- Target (mean)
- 38.50
- Target (high)
- 40.00
Recommendation trend
- 1 month ago 11
- 2 months ago 12
Earnings and revenue estimates
Consensus for the coming quarters and fiscal years
| Period | EPS estimate | Low – high | Year ago | EPS growth | Revenue estimate | Revenue growth | Analysts |
|---|---|---|---|---|---|---|---|
| Current quarter | -0.53 | -0.56 – -0.51 | -0.41 | -29.3% | 0 | 0.0% | 2 |
| Next quarter | -0.52 | -0.53 – -0.52 | -0.35 | -48.6% | 6.51M | 0.0% | 2 |
| Current year | -1.91 | -2.10 – -1.59 | -1.53 | -24.8% | 11.81M | 0.0% | 3 |
| Next year | -1.48 | -2.28 – -1.01 | -1.91 | +22.5% | 142.63M | +1107.7% | 3 |
Upgrades and downgrades
The latest rating changes
| Date | Firm | Action | From | To |
|---|---|---|---|---|
| May 8, 2023 | TD Cowen | Downgrade | Outperform | Market Perform |
| May 4, 2023 | Baird | Downgrade | Outperform | Neutral |
| May 3, 2023 | UBS | Downgrade | Buy | Neutral |
| May 2, 2023 | HC Wainwright & Co. | Downgrade | Buy | Neutral |
| May 1, 2023 | Wedbush | Downgrade | Outperform | Neutral |
| May 1, 2023 | Guggenheim | Downgrade | Buy | Neutral |
| Apr 25, 2023 | Morgan Stanley | Maintained | — | Overweight |
| Apr 3, 2023 | Wedbush | Reiterated | — | Outperform |
| Mar 2, 2023 | HC Wainwright & Co. | Reiterated | — | Buy |
| Feb 21, 2023 | B. Riley Securities | Maintained | — | Neutral |
| Feb 17, 2023 | HC Wainwright & Co. | Reiterated | — | Buy |
| Nov 10, 2022 | Jefferies | Downgrade | Buy | Hold |
| Nov 4, 2022 | HC Wainwright & Co. | Maintained | — | Buy |
| Sep 8, 2022 | Stifel | Maintained | — | Buy |
| Sep 7, 2022 | Guggenheim | Maintained | — | Buy |
| Sep 7, 2022 | Baird | Maintained | — | Outperform |
| Sep 6, 2022 | B. Riley Securities | Downgrade | Neutral | Sell |
| Aug 29, 2022 | B. Riley Securities | Initiated | — | Neutral |
| Aug 2, 2022 | UBS | Initiated | — | Buy |
| Jul 7, 2022 | Morgan Stanley | Maintained | — | Overweight |
| Jun 8, 2022 | Guggenheim | Initiated | — | Buy |
| Jun 8, 2022 | B of A Securities | Initiated | — | Buy |
| Mar 22, 2022 | Jefferies | Initiated | — | Buy |
| Mar 3, 2022 | Baird | Initiated | — | Outperform |
| Feb 7, 2022 | Morgan Stanley | Initiated | — | Overweight |
| Nov 10, 2021 | HC Wainwright & Co. | Maintained | — | Buy |
| Sep 10, 2021 | Credit Suisse | Maintained | — | Outperform |
| Sep 10, 2021 | Stifel | Initiated | — | Buy |
| Aug 19, 2021 | HC Wainwright & Co. | Initiated | — | Buy |
| Aug 13, 2020 | Credit Suisse | Initiated | — | Outperform |